TITLE:
Study of Karenitecin (BNP1350) to Treat Malignant Melanoma

CONDITION:
Melanoma

INTERVENTION:
Karenitecin (BNP1350)

SUMMARY:

      The purpose of this study is to evaluate the safety and efficacy of Karenitecin (BNP1350) as
      a treatment for Malignant Melanoma.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        -  Confirmed diagnosis of malignant melanoma

          -  Measurable disease

          -  Granulocytes 1,500/l, Platelets 100,000/l, Creatinine ULN, Bilirubin 1.5 mg/dl,
             AST 2.5 x ULN

          -  No prior treatment with other camptothecin drug.

          -   21 days since completion of prior chemotherapy, 6 weeks since prior Mitomycin-C

          -  ECOG Performance Status 0-1

          -  Negative pregnancy test for female patients
      
